Ohm Laboratories, a unit of Indian drug firm Ranbaxy Laboratories, received a warning letter from the FDA regarding manufacturing violations at a Gloversville, N.Y., facility. Ranbaxy said the agency "did not observe any material deviation" in the unit's other facilities in the U.S. and that it plans to cooperate with the agency.

Related Summaries